149 related articles for article (PubMed ID: 38688588)
1. Systemic Scleroderma Induced by Nivolumab in Malignant Melanoma.
Loupret T; Boisseau R; Lopez JG; Bertin P; Vergne-Salle P
In Vivo; 2024; 38(3):1451-1453. PubMed ID: 38688588
[TBL] [Abstract][Full Text] [Related]
2. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
3. Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma.
Gambichler T; Seifert C; Lehmann M; Lukas C; Scheel C; Susok L
Immunotherapy; 2020 May; 12(7):439-444. PubMed ID: 32308086
[No Abstract] [Full Text] [Related]
4. Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature.
Kosche C; Stout M; Sosman J; Lukas RV; Choi JN
Melanoma Res; 2020 Jun; 30(3):313-316. PubMed ID: 31567590
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab-induced systemic lymphadenopathy occurring during treatment of malignant melanoma: a case report.
Kubo T; Hino A; Fukushima K; Shimomura Y; Kurashige M; Kusakabe S; Nagate Y; Fujita J; Yokota T; Kato H; Shibayama H; Tanemura A; Hosen N
Int J Hematol; 2022 Aug; 116(2):302-306. PubMed ID: 35201591
[TBL] [Abstract][Full Text] [Related]
6. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature.
Messer A; Drozd B; Glitza IC; Lu H; Patel AB
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941716
[TBL] [Abstract][Full Text] [Related]
7. Case Report: A Variety of Immune-Related Adverse Events Triggered by Immune Checkpoint Inhibitors in a Subject With Malignant Melanoma: Destructive Thyroiditis, Aseptic Meningitis and Isolated ACTH Deficiency.
Katakura Y; Kimura T; Kusano T; Tatsumi F; Iwamoto Y; Sanada J; Fushimi Y; Shimoda M; Kohara K; Nakanishi S; Kaku K; Mune T; Kaneto H
Front Endocrinol (Lausanne); 2021; 12():722586. PubMed ID: 34712202
[TBL] [Abstract][Full Text] [Related]
8. A rare case of eosinophilic gastritis induced by nivolumab therapy for metastatic melanoma.
Tsuji A; Hiramatsu K; Namikawa S; Yamamoto A; Midori Y; Murata Y; Tanaka T; Nosaka T; Naito T; Takahashi K; Ofuji K; Matsuda H; Ohtani M; Imamura Y; Iino S; Hasegawa M; Nakamoto Y
Clin J Gastroenterol; 2022 Oct; 15(5):876-880. PubMed ID: 35978213
[TBL] [Abstract][Full Text] [Related]
9. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R;
J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011
[TBL] [Abstract][Full Text] [Related]
10. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
[TBL] [Abstract][Full Text] [Related]
11. The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies.
Wu CE; Yang CK; Peng MT; Huang PW; Chang CF; Yeh KY; Chen CB; Wang CL; Hsu CW; Chen IW; Lin CT; Ueng SH; Lin G; Lin YF; Cheng CY; Chang JW
BMC Cancer; 2020 Oct; 20(1):1018. PubMed ID: 33087090
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
13. Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report.
Langan EA; Budner K; Zillikens D; Terheyden P
Medicine (Baltimore); 2021 Apr; 100(16):e25513. PubMed ID: 33879687
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab-induced multiple morphea associated with eosinophilic fasciitis.
Lacombe M; Bedane C; Delaumenie S; Bernard P
Eur J Dermatol; 2021 Dec; 31(6):844-846. PubMed ID: 34911674
[No Abstract] [Full Text] [Related]
15. Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma.
Zhao JJ; Wen XZ; Ding Y; Li DD; Zhu BY; Li JJ; Weng DS; Zhang X; Zhang XS
Aging (Albany NY); 2020 Jun; 12(11):10663-10675. PubMed ID: 32516130
[TBL] [Abstract][Full Text] [Related]
16. Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
McDonald MA; Sanghvi P; Bykowski J; Daniels GA
BMC Cancer; 2018 May; 18(1):549. PubMed ID: 29743050
[TBL] [Abstract][Full Text] [Related]
17. Acute renal transplant rejection following nivolumab therapy for metastatic melanoma.
Tan B; Baxter M; Casasola R
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33558380
[TBL] [Abstract][Full Text] [Related]
18. Polymyalgia rheumatica in a melanoma patient 11 months after completion of immunotherapy with nivolumab.
Lobo Y; Good P; Murphy F
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1244. PubMed ID: 32671986
[TBL] [Abstract][Full Text] [Related]
19. Two Cases of Durable and Deep Responses to Immune Checkpoint Inhibition-Refractory Metastatic Melanoma after Addition of Camu Camu Prebiotic.
Pang SA; Elkrief A; Capella MP; Miller WH
Curr Oncol; 2023 Aug; 30(9):7852-7859. PubMed ID: 37754485
[TBL] [Abstract][Full Text] [Related]
20. A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.
Belkaid S; Berger M; Nouvier M; Picard C; Dalle S
Eur J Cancer; 2020 Nov; 139():169-172. PubMed ID: 32992155
[No Abstract] [Full Text] [Related]
[Next] [New Search]
